Takeda Pharmaceutical announced the launch of Ozeiflu, a narcolepsy drug, in Japan and China. JCR Pharmaceuticals’ Izkargo also received approval in Kuwait.
Takeda Pharmaceutical announced the launch of Ozeiflu, a treatment for narcolepsy type 1, in Japan and China. Ozeiflu is an orexin 2 receptor agonist, and Takeda Pharmaceutical expects peak global sales of $2 billion to $3 billion.
The drug was approved in China in July and Japan in August, and was also approved in the United States in August. The Japanese prices are ¥22,773.30 for the 0.5 mg tablet, ¥22,792.50 for the 1 mg tablet and ¥22,838.80 for the 2 mg tablet. Annual sales at peak are expected to reach ¥7.04 billion.
JCR Pharmaceuticals announced on 14 October that its Hunter syndrome treatment Izkargo had been approved in Kuwait. This is the second approval in the Middle East and North Africa region, after the United Arab Emirates, and the company has entered into a distribution agreement with Taiba Middle East. The drug has been marketed in Japan since 2021.
Among other developments, AnswersNews also highlighted related news and encouraged attention to future developments.